Tag: TOBA II BTK

tack

Intact Vascular announces positive one-year data from TOBA II BTK clinical...

Intact Vascular announced the positive one-year results from its Tack optimised balloon angioplasty (TOBA) II BTK clinical trial during the 2020 Vascular Interventional Advances (VIVA)...

First US commercial use of Tack Endovascular System in BTK arteries...

Intact Vascular has announced the first commercial use of its Tack Endovascular System (4F) in multiple sites across the USA. Notably the first FDA-approved...
tack

VIVA 2019: TOBA II BTK meets primary safety and efficacy endpoints...

It was announced today at the 2019 Vascular Interventional Advances conference (VIVA) (4–7 November, Las Vegas, USA) that, through six months, TOBA II BTK...
enrolment

TOBA II BTK clinical trial completes enrolment

The Tack Optimised Balloon Angioplasty II below-the-knee (TOBA II BTK) clinical trial has successfully completed enrolment, ahead of schedule. This study, sponsored by Intact...

Intact Vascular announces presentation of TOBA II pivotal data

Intact Vascular has announced that data from its Tack Optimized Balloon Angioplasty (TOBA) II pivotal study will be presented as a late-breaking clinical trial...

Tack Endovascular System secures US$20 million in premarket approval funding

Intact Vascular, a developer of medical devices for minimally invasive peripheral vascular procedures, has announced that it closed a Series C financing totaling US$20 million....

TOBA BTK trial study publishes one-year results for Tack endovascular system

The TOBA BTK (Tack Optimized Balloon Angioplasty Below the Knee) clinical trial results have recently been published in Catheterization and Cardiovascular Intervention. The multicentre...

Intact Vascular announces enrolment of first European patient in TOBA II...

Intact Vascular’s TOBA II BTK (Tack optimized balloon angioplasty II below the knee) clinical trial has commenced enrolment in Europe, with the first patient treated by Marianne Brodmann and Peter Reif...

FDA approves six-month primary endpoint for Tack endovascular system in below-the-knee...

The US Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplemental application to modify the primary endpoint in Intact Vascular’s TOBA II...

TOBA II BTK clinical trial commences enrolment with first implant of...

Intact Vascular’s TOBA II BTK (Tack optimised balloon angioplasty II below the knee) clinical trial has commenced enrolment, with the first patient treated by Joseph Cardenas at Yuma Regional Hospital and...

FDA approves TOBA II BTK pivotal IDE clinical study

The US Food and Drug Administration (FDA) has granted staged approval for Intact Vascular’s investigational device exemption (IDE) application to begin its TOBA II BTK...